Abeona Therapeutics Inc. (ABEO)
$7.36
Insights on Abeona Therapeutics Inc.
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 320.1%
Performance
- $7.27$7.73$7.36
1.22%
Downside
Day's Volatility :5.95%
Upside
4.79%
- $2.83$9.01$7.36
61.55%
Downside
52 Weeks Volatility :68.59%
Upside
18.31%
Returns
| Period | Abeona Therapeutics Inc. | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | 51.13% | 0.0% | 0.0% |
6 Months | 84.46% | 0.0% | 0.0% |
1 Year | 117.11% | -1.3% | -1.3% |
3 Years | -81.83% | -22.1% | -22.1% |
Highlights
Market Capitalization | 207.1M |
Book Value | $0.56 |
Earnings Per Share (EPS) | -2.53 |
PEG Ratio | 0.0 |
Wall Street Target Price | 21.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1377.14% |
Return On Assets TTM | -46.99% |
Return On Equity TTM | -260.6% |
Revenue TTM | 3.5M |
Revenue Per Share TTM | 0.16 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -28.0M |
EBITDA | -45.9M |
Diluted Eps TTM | -2.53 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.92 |
EPS Estimate Next Year | -1.1 |
EPS Estimate Current Quarter | -0.47 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 185.33%
Technicals Summary
Sell
Neutral
Buy
Abeona Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Abeona Therapeutics Inc. | -0.54% | 84.46% | 117.11% | -81.83% | -96.43% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Abeona Therapeutics Inc. | 0.06 | NA | 0.0 | -1.92 | -2.61 | -0.47 | NA | 0.56 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Abeona Therapeutics Inc. | Buy | $207.1M | -96.43% | 0.06 | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Nantahala Capital Management, LLC
16.45%Adage Capital Partners Gp LLC
11.88%Millennium Management LLC
5.19%Point72 Asset Management, L.P.
4.32%Vanguard Group Inc
4.03%Western Standard LLC
2.95%
Company Information
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Organization | Abeona Therapeutics Inc. |
Employees | 84 |
CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Industry | Health Technology |
